A Phase I study of olaparib and irinotecan in patients with colorectal cancer: Canadian Cancer Trials Group IND 187
Conclusions Olaparib can be combined with irinotecan if administered intermittently. Both olaparib and irinotecan required significant dose reductions. The lack of anti-tumor efficacy observed in this trial makes this combination of little interest for further clinical development. Trial Registration ID NCT00535353.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Anorexia | Cancer | Cancer & Oncology | Colon Cancer | Colorectal Cancer | Drugs & Pharmacology | Eating Disorders & Weight Management | Investigational New Drugs | Pain | Study | Thrombocytopenia | Toxicology